COVID-19 breakthrough infections in rheumatic diseases patients after vaccination

• Egile Nagusiak: Abeer N. Alshukairi (Egilea), Awad Al-Omari (Egilea), Abdurahman Albeity (Egilea), Thamir A. Alandijany (Egilea), Ahmed M. Hassan (Egilea), Sherif A. El-Kafrawy (Egilea), Ashraf Dada (Egilea), Mohammad K. Al Hroub (Egilea), Aiman El-Saed (Egilea), Lina S. Bissar (Egilea), Radwan M. Daghmush (Egilea), Saeed M.G. Al-Ghamdi (Egilea), Stanley Perlman (Egilea), Esam I. Azhar (Egilea), Hussein Halabi (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2022-06-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Background: Rheumatic diseases patients receiving Rituximab had severe COVID-19 disease. Although they had impaired humoral immune responses following COVID-19 vaccine, they had preserved cellular immune responses. Waning of COVID-19 antibody responses was observed within six months post vaccination...